Changes in Hong Kong stocks | Junshi Biotech (01877) rose more than 4% and reached a strategic cooperation with Meijie Medical to explore “multi-modal drug combination” for cancer treatment

The Zhitong Finance App learned that Junshi Biotech (01877) rose more than 4%. As of press release, it had risen 4.03% to HK$19.09, with a turnover of HK$23.2684 million.

According to news, according to Junshi Biotech's official WeChat, the company announced that it has recently formally signed a strategic cooperation agreement with Meijie Medical. The two sides will carry out comprehensive strategic cooperation on core directions such as “multi-modal thermophysical immunomodulation platform technology and drug joint clinical research, and new drug target exploration” to lead tumor treatment into a new era of “multi-modal drug combination”. The focus of this collaboration is to break traditional industry boundaries, systematically integrate precise local intervention with systemic immune activation, and establish a new treatment model called “interventional immunization”.

The two sides will focus on initiating joint clinical research and accumulating data to clarify the efficacy and safety characteristics of the joint plan in target indications; explore the viability of the “drug combination” scheme to obtain regulatory approval to form a replicable registration and commercialization path; and hope to expand this model to more tumors and treatment combinations, promote “drug combination” to become one of the standard options for cancer treatment, and explore the possibility of extending it to overseas markets.